Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia-II study of intratumoral FOLactis in advanced solid tumors
ChiCTR2500095592Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of FOLactis in Nonhematologic neoplasms (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
FOLactis
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500095592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095592.